MS Patients Seen to Safely Switch to Oral Drugs from Injectable Oral Therapies

List of Hepatitis C Drugs – Direct Acting Antivirals
February 10, 2016
Cancer Treatment Has Come A Long Way In 2015: These Are The 5 Biggest Breakthroughs
February 10, 2016
Show all

MS Patients Seen to Safely Switch to Oral Drugs from Injectable Oral Therapies

Switching from injectable treatment with IFNβ/GA to oral therapy for multiple sclerosis does not increase the risk of relapse, says new research.

Stable multiple sclerosis (MS) patients do not appear to be at any increased risk of disease reactivation while switching to oral therapy following treatment with injectable interferon-β/glatiramer acetate (IFNβ/GA), a study reports.

Recently published in the European Journal of Neurology, the Australian study was titled “Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.“

Earlier research had raised concerns that people switching to the oral immunomodulating drug fingolimod (Gilenya) could be at increased risk of MS relapse, but little data has been collected on the six-month period following a switch in treatments.

The research team from the Royal Melbourne Hospital compared 396 MS patients moving from IFNβ/GA to oral drugs to an equal number of MS patients who remained on the injectable treatment. The study analyzed data from patients who had been stable on the IFNβ/GA treatment for at least the previous 12 months.

The team analyzed the frequency of relapse and disability progression, and found no differences between the two groups, either in the rate of relapse or in disease progression. Relapses in both groups were relatively rare, with 7.3 percent of the switchers experiencing a relapse, compared to 6.6 percent of patients remaining on injectable treatment.

Researchers also analyzed patients divided into subgroups based on the type of oral treatment given. Most switched to fingolimod (71.2 percent), but 16.2 percent moved to dimethyl fumarate, and the remaining to teriflunomide. Again, the researchers could not detect any differences in relapse rate among patients in these three groups. The time of washout of IFNβ/GA treatment also was not linked to an increased relapse risk or disease progression.

Read Full Article: MS Patients Seen to Safely Switch to Oral Drugs from Injectable Oral Therapies – Multiple Sclerosis News Today

Comments are closed.